Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
Limited Edition Golden Llama is here! Check out how you can get one. Limited Edition Golden Llama is here! Check out how you can get one.
Offering SPR-BLI Services - Proteins provided for free!Get your ComboX free sample to test now!
Time Limited Offer: Welcome Gift for New Customers ! Shipping Price Reduction for EU Regions
Assay Type | Sandwich-ELISA |
Analyte | IFN-γ |
Format | 96T |
Reactivity | Human |
Sensitivity | 4pg/mL |
Standard Curve Range | 7.81 pg/mL-1000 pg/mL |
Assay Time | 2 hr |
Suitable Sample Type | For the quantitative determination of human IFN-γ in Cell Culture Supernatants, Plasma, Serum. |
Sample volume | 50 uL |
ID | Components | Size |
CEA006-C01 | Pre-coated Anti-IFN-γ Ab Microplate | 1 plate |
CEA006-C02 | IFN-γ Calibrator | 15 μg×2 |
CEA006-C03 | Biotin-Anti-IFN-γ Ab Con. Solution | 100 μL |
CEA006-C04 | Biotin-Ab Dilution Buffer | 8 mL |
CEA006-C05 | IFN-γ SA-HRP Con. Solution | 0.5 mL |
CEA006-C06 | SA-HRP Dilution Buffer | 15 mL |
CEA006-C07 | 20×Washing Buffer | 50 mL |
CEA006-C08 | Sample Dilution Buffer | 15 mL×2 |
CEA006-C09 | Substrate Solution | 12 mL |
CEA006-C10 | Stop Solution | 6 mL |
A comprehensive validation of the ELISA method was performed following the ICH M10 on bioanalytical method validation and the FDA’s bioanalytical method validation guidance for industry. This validation included assessments of linearity, accuracy, precision, dilution linearity, recovery, and the hook effect. For details information, please refer to the DS.
ClinMax™ ELISA Kits are manufactured in a GMP-certified facility and comply to the ISO 13485 standard, ensuring a high level of quality and reliability.
Results are obtained by Log-Log Linear regression equation are used to draw the standard curve and calculate the sample concentration. The verification results indicate that this kit can be used for the quantitative determination of natural and recombinant human IFN-γ concentrations.
It has been calibrated against a highly purified human IFN-γ and is evaluated with standard from NIBSC/WHO. Reference Reagent INTERFERON GAMMA (Human, rDNA derived) NIBSC code: 87/586.
It is for research use only.
For each experiment, each ELISA plate needs to set the standard curve. The minimum detectable concentration of CEA-C006 is less than 4.0 pg/mL.
Ten replicates of each of five samples containing different IFN-γ concentrations were tested in one assay, Intra-Assay Precision CV<10%.
Five samples containing different concentrations of IFN-γ were tested in three independent assays, Inter-Assay Precision CV<15%.
Recombinant IFN-γ(8000,6000,4000pg/mL)was spiked into 5 human serum samples, and then analyzed. On average, 98.28% of IFN-γ was recovered from serum samples.
Price(EUR) : €550.00
Price(EUR) :
Price(EUR) :
Explore our catalog of therapeutic antibody solutions to find the right products for you! We are dedicated to delivering solutions designed to help you drive innovation and push the boundaries of what therapeutic antibodies can be.
We offer a wide range of cell and gene therapy solutions starting from discovery to the clinic. Explore our wide range of proteins, antibodies, kits, and other assays to accelerate the development of your cell and gene therapy.
Organoid Toolbox is a collection of organoid solutions including ready-to-use organoids, organoid differentiation kits, and a variety of services to accelerate the progress of your drug development project.
ACROBiosystems developed a series of GMP grade cytokines under the GMP grade quality management system. Those products are all suitable for T/NK cell generation, activation, and proliferation in cell therapy research.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
GMP grade cytokines, reagents for cell activation, gene edition, DNA/RNA removal, etc. Particularly focus on product design, quality control and solution-based support to link each phase of your cell and gene therapy journey.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2, CD133, GPRC5D,CCR8, CCR5, etc.
A series of immune checkpoints including classic co-inhibitory and co-stimulatory receptors. The comprehensive catalog contains 100+ targets with various species and tags, and the high-quality proteins are in good batch-to-batch consistency.
To meet the needs of ADCs development, ACROBiosystems can provide: A variety of high-quality target proteins; MMPs/Cathepsin/uPA for cleavable linker; Anti-payload antibodies & anti-idiotypic antibodies for immunogenicity and PK analysis; SPR/BLI analytical and ADA development service.
Comprehensive collection of Fc receptor proteins, including their common variants, which can help expedite your antibody development.
Comprehensive cytokine targets including interleukins, growth factors, chemokines, TNFs, etc. are expressed by HEK293 to ensure their natural structure. Their high purity is verified by SDS-PAGE/HPLC/SEC-MALS and high bioactivity is verified by ELISA/SPR/BLI.
Aneuro provides innovative solutions for neuroscience research. Recombinant proteins, neural factors, pre-formed fibrils, electrophysiological electrodes, as well as Organoid Toolbox all in Aneuro aiming to advance neuroscience research, develop therapeutic interventions, and improve diagnostic methods for neurological diseases.
English Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Fecha | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Cadi-05 | Cadi-05 | Approved | National Institute Of Allergy And Infectious Diseases (Niaid) | Immuvac, Leprovac, Mycidac-C | India | Carcinoma, Non-Small-Cell Lung; Leprosy | null | 1998-01-01 | Leprosy; Carcinoma, Non-Small-Cell Lung | Details |
Emapalumab | NI-0501 | Approved | Novimmune Sa | Gamifant | United States | Lymphohistiocytosis, Hemophagocytic | Novimmune Sa | 2018-11-20 | Macrophage Activation Syndrome; Still's Disease, Adult-Onset; Rare Diseases; Immune System Diseases; Arthritis, Juvenile; Lupus Erythematosus, Systemic; Lymphohistiocytosis, Hemophagocytic | Details |
Thalidomide | NSC-66847; NSC-527179; K-17; VP-02; FPF-300; FPF300 | Approved | Celgene Corp | Talizer, Thalidomide Celgene, Thalidomide Pharmion, Synovir, Thalomid, Thaled | Mainland China | Leprosy, Lepromatous; Multiple Myeloma | Changzhou Pharmaceutical Factory | 1982-01-01 | HIV Wasting Syndrome; Angiodysplasia; Primary Myelofibrosis; Neuroectodermal Tumors, Primitive; Prostatitis; Colorectal Neoplasms; Osteosarcoma; Lymphoma, Mantle-Cell; Sarcoma, Ewing; Retinoblastoma; Erythema Nodosum; Drug Resistant Epilepsy; Xerostomia; Sarcoma; Pancreatitis, Chronic; Adenocarcinoma, Clear Cell; Lymphoma, Follicular; Arachnoiditis; Carcinoma, Adenosquamous; Gastrointestinal Hemorrhage; Cholangitis, Sclerosing; Prostatic Neoplasms; Pelvic Pain; Neoplasm Metastasis; Stomatitis; Burning Mouth Syndrome; Mycobacterium avium-intracellulare Infection; Amyotrophic Lateral Sclerosis; Melanoma; Myelodysplastic-Myeloproliferative Diseases; Carcinoma, Hepatocellular; Leukemia, Lymphocytic, Chronic, B-Cell; Vascular Malformations; Tuberculosis; Appendiceal Neoplasms; Lymphoma, Non-Hodgkin; Uterine Neoplasms; Anemia, Sideroblastic; Glioma; Leprosy, Lepromatous; Endometrial Neoplasms; Lung Neoplasms; Waldenstrom Macroglobulinemia; Kidney Neoplasms; Thalassemia; Carcinoid Tumor; Lupus Erythematosus, Discoid | Details |
English Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Tadekinig alfa (AB2 Bio) | Phase 3 Clinical | Ab2 Bio Ltd | Macrophage Activation Syndrome; Cytokine Release Syndrome; Lymphohistiocytosis, Hemophagocytic | Details | |
PDS-0101 | PDS-0101B; PDS-0101C; PDS-0101; PDS-0101A; PDS-101 | Phase 2 Clinical | Pds Biotechnology Corporation, Merck Serono | Head and Neck Neoplasms; Anus Neoplasms; Papillomavirus Infections; Vulvar Neoplasms; Oropharyngeal Neoplasms; Carcinoma, Squamous Cell; Uterine Cervical Neoplasms | Details |
YH-32367 | ABL105; YH-32367 | Phase 2 Clinical | Abl Bio Inc | Solid tumours; Stomach Neoplasms; Breast Neoplasms | Details |
OCH-NCNP1 | OCH-NCNP1 | Phase 2 Clinical | Keio University | Multiple Sclerosis; Crohn Disease | Details |
KIO-101(Kiora) | PP-001; KIO-101 | Phase 2 Clinical | 4sc Ag | Dry Eye Syndromes; Eye Diseases; Keratoconjunctivitis; Uveitis; Xerophthalmia; Conjunctival Diseases | Details |
ASN-002 (Ascend Biopharmaceuticals) | TG-1042; Ad-IFNγ; SP-002 (Ascend Biopharmaceuticals) | Phase 2 Clinical | Transgene Sa | Solid tumours; Lymphoma, B-Cell; Carcinoma, Basal Cell; Skin Neoplasms; Basal Cell Nevus Syndrome; Melanoma | Details |
IFN-gamma-secreting HAdV antigen specific T cells (Case Comprehensive Cancer Center) | Phase 1 Clinical | Case Comprehensive Cancer Center | Hematopoietic stem cell transplantation (HSCT) | Details | |
Recombinant human interferon gamma adenovirus injection (Guangzhou Dabo Biological Products) | Phase 1 Clinical | Guangzhou Dabo Biological Products Co Ltd | Liver Neoplasms; Nasopharyngeal Neoplasms; Prostatic Neoplasms, Castration-Resistant | Details | |
EI-001 | EI-001 | Phase 1 Clinical | Elixiron Immunotherapeutics Inc | Vitiligo | Details |
This web search service is supported by Google Inc.